Therapeutic Solutions International, Inc. Recruits Top Doctor of San Diego to Scientific Advisory Board
February 27 2018 - 9:00AM
InvestorsHub NewsWire
Therapeutic Solutions
International, Inc. Recruits Top Doctor of San
Diego to Scientific Advisory Board
Dr. James Veltmeyer to Assist
Company in Expansion of Clinical Applications of Pterostilbene
Based Therapeutics
Oceanside, CA --
February 27, 2018 -- InvestorsHub
NewsWire
--
Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced today
that James Drew Veltmeyer,
M.D., has been appointed
to the Company's
Scientific Advisory
Board.
Dr.
James Veltmeyer, MD is a board certified family physician in La
Mesa, California. A graduate of UC San
Diego and the Ross University School of Medicine, he completed his
residency through the UC San Francisco system where he became
Chief of Family Medicine
Residency, overseeing 36
doctors. Dr. Veltmeyer, a member of the San Diego Critical Care
Medical Group, has been elected for four
years (2012, 2014, 2016, and 2017) by his colleagues
in the San Diego County Medical Society as a "Physician of
Exceptional Excellence," the most prestigious honor awarded to a
"Top Doctor" in San Diego County. He is among a select group of San
Diego physicians who was chosen four of the last fifteen years and
he consistently ranks in the top 1% to 2% for patient satisfaction.
He is currently the Chief of the Department of Family Medicine at
Sharp
Grossmont
Hospital
where he
provides senior leadership to over 200 doctors.
"It is
our
great
pleasure to
welcome
Dr. James
Veltmeyer to our Scientific
Advisory Board. Dr.
Veltmeyer
in
coming to this country at
age eleven after suffering homelessness and hardship in his
South American country
of birth, Dr. Veltmeyer has achieved phenomenal success because he
had an opportunity to come to the United States and enter our
educational system where he pursued the field of
medicine.
We are deeply honored to have Dr. Veltmeyer on our distinguished
scientific team", said Timothy Dixon,
President and CEO.
"I am
enthusiastic
to work
besides the team assembled by Mr. Dixon in advancing the
commercialization of the patented pterostilbene-based
immunotherapeutic products for treatment of cancer and other
medical conditions", said
Dr.
Veltmeyer.
"Dr.
Veltmeyer
possesses
unparalleled insight in the practice of medicine. Combined with his
unique curiosity and problem solving mindset, we are very eager to
begin our collaborations with Dr. Veltmeyer, which we believe will
translate into new treatments for patients." said Dr. Thomas
Ichim, Board Member of TSOI and CEO of Emvolio,
Inc.
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com.
Safe
Harbor Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT INFORMATION
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Sep 2023 to Sep 2024